-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nivolumab (Nivolumab, trade name Opdivo, Chinese trade name Odivo) is a fully humanized anti-PD-1 monoclonal antibody for the treatment of cancer.
The drug is mainly used as a first-line drug in combination with Ipilimumab (Ipilimumab) to treat unresectable or metastatic melanoma, and as a second-line drug in combination with BRAF inhibitors (such as verofenib) to treat melanoma with BRAF mutations .
Recently, the results of the randomized, phase III, open-label CheckMate 816 trial announced at the 2021 virtual annual meeting of the American Association for Cancer Research (AACR) showed that compared with chemotherapy alone, the neoadjuvant immunotherapy drug nivolumab plus platinum Dual chemotherapy significantly increased the pathological complete response (pCR) rate in patients with resectable stage IB to IIIA non-small cell lung cancer ( NSCLC ).
Compared with chemotherapy alone, the neoadjuvant immunotherapy drug nivolumab plus platinum-based dual chemotherapy significantly increased the pathological complete response (pCR) rate in patients with resectable stage IB to IIIA non-small cell lung cancer ( NSCLC ).
The pCR rate of nivolumab plus chemotherapy was 24%, compared with 2.
In this study, patients were randomly assigned to two groups receiving 360 mg Navuriuga every 3 weeks (3 cycles) and chemotherapy alone.
77% and 61% of patients underwent lung resection respectively.
According to the intention-to-treat (ITT) analysis, adding Navuriu to chemotherapy can increase the pCR rate from 2.
In the subgroup analysis, the pCR benefit of Navuriga chemotherapy was maintained by stage, histology, PD-L1 status, and tumor mutation burden.
When Navuriu is given, circulating tumor (ct) DNA is easier to clear, increasing the possibility of complete pathological remission.
Dr.
When Navulio joined neoadjuvant chemotherapy, we were encouraged by the obvious improvement of pCR, good overall tolerability, and the feasibility of surgery that did not affect surgery.
In the future, I hope that neoadjuvant immunotherapy can bring more good news to more NSCLC and even other cancer patients! In the future, I hope that neoadjuvant immunotherapy can bring more good news to more NSCLC and even other cancer patients!
references:
com/news/april-2021/neoadjuvant-nivolumab-plus-chemotherapy-boosts-pathologic-complete-response-rate-for-patients-with-resectable-nsclc/" target="_blank" rel="noopener">Nivolumab + platinum-doublet chemotherapy vs chemotherapy as neoadjuvant treatment for resectable (Ib-IIIa) non-small cell lung cancer in the phase III CheckMate 816 trial.
com/news/april-2021/neoadjuvant-nivolumab-plus-chemotherapy-boosts-pathologic-complete-response-rate-for-patients-with-resectable-nsclc/" target="_blank" rel="noopener">Nivolumab + platinum-doublet chemotherapy vs chemotherapy as neoadjuvant treatment for resectable (Ib-IIIa) non-small cell lung cancer in the phase III CheckMate 816 trial.
Leave a message here
